close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Iantrek, Inc.

News headline image
Iantrek Announces Commercial Launch of AlloFlo™ Uveo, the Only Surgical Treatment Targeting the Uveoscleral Pathway in Glaucoma
From Iantrek, Inc.
Via GlobeNewswire
News headline image
AlloFlo™ Uveo Achieves Key Milestones Ahead of Launch: 7 Peer-Reviewed Studies & 3,000 U.S. Cases
From Iantrek, Inc.
Via GlobeNewswire
News headline image
Iantrek Raises $42 Million Series C to Launch AlloFlo™ Uveo, a Breakthrough Interventional Glaucoma Therapy
From Iantrek, Inc.
Via GlobeNewswire
News headline image
Iantrek Hits 2,000 Procedures for New Bio-Interventional Technology - AlloFlo™ Uveo
From Iantrek, Inc.
Via GlobeNewswire
News headline image
Iantrek Announces Positive 2-Year Results Demonstrating Efficacy and Safety of Its Bio-Interventional Technology for Uveoscleral Outflow Enhancement in Glaucoma Patients
From Iantrek, Inc.
Via GlobeNewswire
News headline image
Iantrek Appoints Adam Szaronos as Chief Executive Officer
From Iantrek, Inc.
Via GlobeNewswire
News headline image
Iantrek Announces First Commercial Cases of its C.Rex Micro-Interventional System for Trabecular Outflow Enhancement
From Iantrek, Inc.
Via GlobeNewswire
News headline image
Iantrek Announces Peer-Reviewed Publication Highlighting 12-Month Safety and Effectiveness Results for its Bio-Interventional Uveoscleral Outflow Technology in Open-Angle Glaucoma Patients
From Iantrek, Inc.
Via GlobeNewswire
News headline image
Iantrek Announces 1-Year Clinical Results of Its Bio-Interventional Technology for Uveoscleral Outflow Enhancement in Open-Angle Glaucoma Patients
From Iantrek, Inc.
Via GlobeNewswire
News headline image
Iantrek Announces Publication of Results of its Bio-interventional Uveoscleral Outflow Technology in Patients with Open-Angle Glaucoma
From Iantrek, Inc.
Via GlobeNewswire
News headline image
Iantrek reports two upcoming American Academy of Ophthalmology presentations of its breakthrough glaucoma surgical technologies, including 1-year results of a novel supraciliary outflow micro-interventional procedure
From Iantrek, Inc.
Via GlobeNewswire
News headline image
12-month clinical results of a novel micro-interventional bio-stenting procedure published in the British Journal of Ophthalmology
From Iantrek, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today